Genesis Therapeutics
- Biotech or pharma, therapeutic R&D
Internal small molecule pipeline against high-value targets (oncology emphasis); molecules discovered via Genesis' AI platform. $300M funding raised from life science + AI investors, and multi-target AI-focused research collaborations with Gilead (Sept 2024) and Incyte (Feb 2025).
Address
BurlingameCalifornia
United States
)
)
){kind=logo}
){kind=logo}
){kind=logo}